Advertisement

HIV Care Today


Do Electronic Health Records Make You a Better (or Worse) Clinician?
By Paul E. Sax, M.D.
December 6, 2015

Earlier this week, JAMA Internal Medicine published a study entitled, "Level of Computer Use in Clinical Encounters Associated with Patient Satisfaction".

A more descriptive title would have been "More Computer Use in Clinical Encounters Associated with Reduced Patient Satisfaction", as here's the take home point:

Read more …


Five (OK, Six) ID/HIV Things to Be Grateful for This Holiday Season, 2015 Edition
By Paul E. Sax, M.D.
November 26, 2015

Some quick ID/HIV gratitude items for 2015, done rapidly as we're hosting a big meal later today.

I wonder what that might be.

Read more …


New HIV Treatment Genvoya Is Really All About the TAF Part
By Paul E. Sax, M.D.
November 10, 2015

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

Read more …


An HIV Vaccine: Imagining the Future of HIV Prevention
By Tian Johnson
November 6, 2015

In this article, South African HIV prevention activist and member of the Vaccine Advocacy Resource Group -- a small, global group of advocates specifically focused on the HIV vaccine research field -- Tian Johnson reflects on his participation in the recent HVTN Conference in Cape Town, his hope for a vaccine and the necessity of advocates' involvement in the search. This first appeared in NGO Pulse.

Read more …


Should Doctors Still Be Allowed to Wear White Coats? You Decide
By Paul E. Sax, M.D.
November 1, 2015

I almost wrote "raging controversy" -- but the adjective "raging" doesn't really fit the sort of people who specialize in Infection Control, who are some of the most measured, data-driven, and methodical individuals in all of medicine. You know the stereotype of the brash, volatile, and cowboy surgeon, the person that everyone tiptoes around?

Read more …


The Most Important HIV Study at IDWeek 2015
By Paul E. Sax, M.D.
October 29, 2015

After reporting my choice for the most important HIV study at ICAAC, I received this email from a colleague:

Read more …


WHO Decision to Recommend Treatment for All With HIV an Easy One -- Now Comes the Hard Part
By Paul E. Sax, M.D.
October 1, 2015

In the newspaper today -- and yes, we still do get it delivered (some habits die hard) -- is this headline: "Millions More Need H.I.V. Treatment, W.H.O. Says"

It's true -- these updated guidelines say that all should be treated soon after diagnosis, regardless of CD4 cell count or whether they have symptoms.

Read more …


Decision to Lower Price of Pyrimethamine a Good One, Especially Given the Weak Defense of the Price Hike
By Paul E. Sax, M.D.
September 24, 2015

The big ID story the past couple of weeks is that the price of pyrimethamine -- a drug that's been available generically for decades -- went from $13.50 to $750 for one pill after the exclusive rights to the drug were purchased by Turing Pharmaceuticals.

Read more …


Electronic Health Record and Drug Prescribing Warnings: The Good, the Bad, the Ugly
By Paul E. Sax, M.D.
September 20, 2015

Recently, an ENT colleague (fictionally named "Clint" below), sent me two emails triggered by drug-drug interaction warnings he received while seeing HIV patients.

Read more …


The Overlooked Secondary Benefits of PrEP
By Howard Grossman, M.D.
September 18, 2015

Pre-exposure prophylaxis (PrEP) against HIV infection utilizing tenofovir/emtricitabine (Truvada) has been nothing short of revolutionary in changing the landscape of HIV prevention. What has been less discussed are the enormous secondary benefits that have followed the introduction of PrEP.

Read more …

 < Prev  |  1  |  2  |  3  |  4  |  5  |  …  |  20  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.